Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Ronnie Charles Mease, Ph.D.

Headshot of Ronnie Charles Mease
  • Associate Professor of Radiology and Radiological Science

Research Interests

Imaging; Cancer; Radiochemistry; Chemistry; Radiotherapy; Radiopharmaceutical design, synthesis, and development more


Ronnie C. Mease, Ph.D., is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science and the Department of Oncology and a member of the Johns Hopkins Kimmel Cancer Center.

A researcher, Dr. Mease is an organic chemist who specializes in radiopharmaceutical design, synthesis, and development for imaging or radiotherapy—specifically, their applications in treating cancer—with much of his research focused on prostate cancer.

Prior to joining Johns Hopkins in 2003, Dr. Mease was a Research Professor of Radiology at The George Washington University and the University of Maryland at Baltimore. He also worked as a scientist in Brookhaven National Laboratory’s Medical Department. more


  • Associate Professor of Radiology and Radiological Science
  • Associate Professor of Oncology

Departments / Divisions

Centers & Institutes


Additional Training

  • Argonne National Laboratory, Argonne, IL, 1987, Radiopharmaceuticals

Research & Publications

Research Summary

Dr. Ron Mease has nearly three decades of experience in producing and purifying radionuclides, and in designing, synthesizing, purifying and testing radiopharmaceuticals and radiochemicals for imaging and radiotherapy.

Dr. Mease’s work has included the design and synthesis of prostate-specific membrane antigen- and prostate-specific antigen-based agents for PET, SPECT and optical prostate-cancer imaging and radiotherapy. He has prepared radio-labeled agents that include monoclonal antibody conjugates (radiometal-labeled) to small molecules (radiometal- and radiohalogen-labeled).

Working in the neuroradiology laboratory of Dr. Martin G. Pompe, Dr. Mease also leads the chemistry arm of the Johns Hopkins Small Animal Imaging Resource Program, which performs pre-clinical and translational cancer research.

His research has been funded by the National Institutes of Health, National Cancer Institute, and U.S. Department of Defense.

Selected Publications

View all on PubMed

Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG. “Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).” J Med Chem. 2013 Aug 8;56(15):6108-21. doi: 10.1021/jm400823w. Epub 2013 Jul 22

Kostova MB, Rosen DM, Chen Y, Mease RC, Denmeade SR. “Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors.” J Med Chem. 2013 Jun 13;56(11):4224-35. doi: 10.1021/jm301718c. Epub 2013 Jun 4

Ravert HT, Dorff P, Foss CA, Mease RC, Fan H, Holmquist CR, Phillips E, McCarthy DJ, Heys JR, Holt DP, Wang Y, Endres CJ, Dannals RF, Pomper MG. “Radiochemical synthesis and in vivo evaluation of [18F]AZ11637326: an agonist probe for the a7 nicotinic acetylcholine receptor.” Nucl Med Biol. 2013 Aug;40(6):731-9. doi: 10.1016/j.nucmedbio.2013.04.005. Epub 2013 May 13

Mease RC, Foss CA, Pomper MG. “PET imaging in prostate cancer: focus on prostate-specific membrane antigen.” Curr Top Med Chem. 2013;13(8):951-62

Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG. “Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.” J Nucl Med. 2012 Dec;53(12):1883-91. doi: 10.2967/jnumed.112.104661

Academic Affiliations & Courses

Graduate Program Affiliation

Division of Vascular & Interventional Radiology, Department of Oncology

Is this you? Edit Profile
back to top button